Minimal influence of tocilizumab on IFN-γ synthesis by tuberculosis antigens

Oxford University Press (OUP) - 2010
Atsushi Ogata1, Masahide Mori2, Shoji Hirano3, Yukihiro Yano2, Takuya Fujikawa2, Masao Kawai1, Yusuke Kuwahara1, Tôru Hirano1, Junsuke Arimitsu1, Keisuke Hagihara1, Yoshihito Shima1, Masashi Narazaki1, Souichirou Yokota2, Tadamitsu Kishimoto4, Ichiro Kawase1, Toshio Tanaka1
1Department of Respiratory Medicine, Allergy and Rheumatic Disease, Osaka University Graduate School of Medicine, 2-2, Yamadaoka, Suita, Osaka 565-0871, Japan
2Department of Respiratory Medicine, National Hospital Organization Toneyama National Hospital, Osaka, Japan
3Division of Infection Control and Prevention, Osaka University Hospital, Osaka, Japan
4Laboratory of Immune Regulation, Osaka University Graduate School of Frontier Biosciences, Osaka, Japan

Tóm tắt

Từ khóa


Tài liệu tham khảo

Gardam MA, Keystone EC, Menzies R, Manners S, Skamene E, Long R, et al. Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management. Lancet Infect Dis. 2003;3:148–55.

Jacobs M, Togbe D, Fremond C, Samarina A, Allie N, Botha T, et al. Tumor necrosis factor is critical to control tuberculosis infection. Microbes Infect. 2007;9:623–8.

Lalvani A. Diagnostic tuberculosis infection in the 21st century. Chest. 2007;131:1898–906.

Hamdi H, Mariette X, Godot V, Weldingh K, Hamid AM, Prejean MV, Baron G, Lemann M, Puechal X, Breban M, Berenbaum F, Delchier JC, Flipo RM, Dautzenberg B, Salmon D, Humbert M, Emilie D; RATIO (Recherche sur Anti-TNF et Infections Opportunistes) Study Group. Inhibition of anti-tuberculosis T-lymphocyte function with tumour necrosis factor antagonists. Arthritis Res Ther. 2006;8:R114.

Saliu OY, Sofer C, Stein DS, Schwander SK, Wallis RS. Tumor-necrosis-factor blockers: differential effects on mycobacterial immunity. J Infect Dis. 2006;194:486–92.

Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an x ray reader-blinded randomised controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.

Smolen JS, Beaulieu A, Rubbert-Roth A, Ramos-Remus C, Rovensky J, Alecock E, et al. Alten R; OPTION Investigators. Effect of interleukin-6 receptor inhibition with tocilizumab in patients with rheumatoid arthritis (OPTION study). A double-blind, placebo-controlled, randomised trial. Lancet. 2008;371:987–97.

Furst DE, Wallis R, Broder M, Beenhouwer DO. Tumor necrosis factor antagonists: different kinetics and/or mechanisms of action may explain differences in the risk for developing granulomatous infection. Semin Arthritis Rheum. 2006;36:159–67.

Diehl S, Rincón M. The two faces of IL-6 on Th1/Th2 differentiation. Mol Immunol. 2002;39:531–6.

Salvana EM, Cooper GS, Salata RA. Mycobacterium other than tuberculosis (MOTT) infection: An emerging disease in infliximab-treated patients. J Infect. 2007;55:484–7.

Korn T, Oukka M, Kuchroo V, Bettelli E. Th17 cells: effector T cells with inflammatory properties. Semin Immunol. 2007;19:362–71.

Thông tin
Thông tin xuất bản

Oxford University Press (OUP)

Thông tin tác giả